Education
About Us
Working with TipRanks
Follow Us
Metagenomi, Inc. (MGX)
NASDAQ:MGX
MGX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.23 - $10.50
Previous CloseN/A
Volume382.73K
Average Volume (3M)403.96K
Market Cap
$47.10M
Enterprise Value-$67.45M
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.79
Next Earnings
May 20, 2025EPS Estimate
-0.61Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.61
Shares Outstanding37,383,472
10 Day Avg. Volume477,489
30 Day Avg. Volume403,956
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.17
Price to Cash Flow (P/CF)-0.60
P/FCF Ratio0.00
Enterprise Value/Market Cap-1.43
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.29
Enterprise Value/Ebitda0.81
Forecast
1Y Price Target
$20.00Price Target Upside1318.44% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Metagenomi, Inc. News
PremiumCompany Announcements
Metagenomi, Inc. Reports 2024 Financial Results and Pipeline ProgressPremiumCompany Announcements
Metagenomi Reports 2024 Financial Results and Updates---
Bulls Say, Bears Say
Bulls Say
Collaborations And FundingMetagenomi leverages several collaborations with Ionis and Affini-T, which could be a good source of continued non-dilutive funds as development advances.
Gene Editing InnovationsMGX has modified the transgene in MGX-001 to a bioengineered FVIII that has higher FVIII activity and could allow for lower AAV dosing.
Market ValuationThe company could be a leader in the gene editing space and the current valuation of MGX is viewed as attractive for its disruptive potential.
Bears Say
Data VariabilityThere is variability from subject to subject in the dataset, with the three NHP subjects experiencing greatly variable levels of FVIII expression outcome.
Preclinical Data ChallengesMetagenomi's candidate shows variability in FVIII expression in NHPs, with some subjects experiencing different outcomes.
Regulatory TimelineMGX plans to engage with regulators in 2025, and an IND/CTA for MGX-001 remains on track for 2026.
---
Ownership Overview
17.84% Insiders
3.95% Mutual Funds
10.74% Other Institutional Investors
61.07% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
MGX FAQ
What was Metagenomi, Inc.’s price range in the past 12 months?
Metagenomi, Inc. lowest stock price was $1.23 and its highest was $10.50 in the past 12 months.
What is Metagenomi, Inc.’s market cap?
Metagenomi, Inc.’s market cap is $47.10M.
When is Metagenomi, Inc.’s upcoming earnings report date?
Metagenomi, Inc.’s upcoming earnings report date is May 20, 2025 which is in 44 days.
How were Metagenomi, Inc.’s earnings last quarter?
Metagenomi, Inc. released its earnings results on Mar 17, 2025. The company reported -$0.37 earnings per share for the quarter, beating the consensus estimate of -$0.749 by $0.379.
Is Metagenomi, Inc. overvalued?
According to Wall Street analysts Metagenomi, Inc.’s price is currently Undervalued.
Does Metagenomi, Inc. pay dividends?
Metagenomi, Inc. does not currently pay dividends.
What is Metagenomi, Inc.’s EPS estimate?
Metagenomi, Inc.’s EPS estimate is -0.61.
How many shares outstanding does Metagenomi, Inc. have?
Metagenomi, Inc. has 37,383,472 shares outstanding.
What happened to Metagenomi, Inc.’s price movement after its last earnings report?
Metagenomi, Inc. reported an EPS of -$0.37 in its last earnings report, beating expectations of -$0.749. Following the earnings report the stock price went down -7.979%.
Which hedge fund is a major shareholder of Metagenomi, Inc.?
Currently, no hedge funds are holding shares in MGX
---
Metagenomi, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$20.00 (1318.44% Upside)
$20.00 (1318.44% Upside)
Hedge Fund Trend
Decreased
By 2.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $5.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days >0.1%
Last 30 Days ▼ 3.7%
Last 30 Days ▼ 3.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-86.02%
12-Months-Change
Fundamentals
Return on Equity
-34.69%
Trailing 12-Months
Asset Growth
-11.03%
Trailing 12-Months
Company Description
Metagenomi, Inc.
Metagenomi, Inc., a gene editing biotechnology company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.
---
MGX Stock 12 Month Forecast
Average Price Target
$20.00
▲(1318.44% Upside)
Technical Analysis
Sangamo Biosciences
―
Editas Medicine
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Beam Therapeutics
―
Best Analysts Covering MGX
1 Year
1 Year Success Rate
0/6 ratings generated profit
1 Year Average Return
-51.18%
reiterated a buy rating 21 days ago
Copying Joseph Thome's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -51.18% per trade.
---